NEW YORK ─ Oxford Immunotec Global on Monday announced that it has entered into a long-term agreement to supply its T-Spot.TB test and associated accessories to the Stop TB Partnership - Global Drug Facility (GDF).
The announcement follows the inclusion of the Oxford Immunotec T-Spot.TB test, a blood test for TB screening, in the GDF's diagnostics catalog for the detection of tuberculosis (TB) infection.
"Inclusion in the GDF's diagnostic catalog makes our test more accessible to countries that are most in need of an accurate, reliable TB test that works in challenging patient populations, including children and those with immunosuppression, who are likely the first targets for new latent TB testing programs," Peter Wrighton-Smith, Oxford Immunotec's CEO, said in a statement.
As a result of the agreement, national TB control programs may now order the T-spot.TB test through the GDF's procurement mechanism.
Created in 2001, the GDF is a global provider of quality-assured TB medicines, diagnostics, and laboratory supplies, and has facilitated access to TB medicines and diagnostics in more than 140 countries, noted Oxford Immunotec, which has offices in Oxford, UK, and Marlborough, Massachusetts.
In 2019, GDF delivered nearly $264 million worth of TB medicines and diagnostics to 116 countries, and it has led the introduction of advanced diagnostic and supplies in countries to support TB diagnosis.